Compare TALK & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TALK | GHRS |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | Ireland |
| Employees | 598 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.7M | 947.2M |
| IPO Year | N/A | 2021 |
| Metric | TALK | GHRS |
|---|---|---|
| Price | $5.23 | $26.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $6.42 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 2.7M | 242.2K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.02 | N/A |
| Revenue Next Year | $21.24 | N/A |
| P/E Ratio | $155.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.22 | $11.32 |
| 52 Week High | $5.24 | $28.96 |
| Indicator | TALK | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 61.07 |
| Support Level | $5.19 | $12.88 |
| Resistance Level | $5.23 | $28.96 |
| Average True Range (ATR) | 0.02 | 1.69 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 72.73 | 71.44 |
Talkspace Inc is a virtual behavioral healthcare company offering its members convenient and affordable access to a fully-credentialed network of qualified providers across a wide and growing spectrum of care through virtual psychotherapy and psychiatry. It is a single destination for comprehensive mental health care, including therapy for individuals, couples, and teens, as well as psychiatric treatment and medication management (18+), and self-guided tools and resources. The company's customers include Health insurance plans from commercial and government institutions, and employee assistance programs, Direct-to-Enterprise, and Individual subscribers. The company operates as a single segment.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.